2nd Meeting of the Nutrition Support Working Group 16th Congress of Asia-Pacific Blood and Marrow Transplantation Group Oct 31, 2011 (Sydney)

Proposal of Clinical Trial


Sung-Won Kim, M.D., Ph.D. skim@ncc.go.jp

Department of Hematology and Stem Cell Transplantation
National Cancer Center Hospital
Tokyo, Japan

International randomized phase III study of glucose control

- After NST01 study, we have to plan a large scale phase III study of glucose control.
- In only Japan, patient recruitment is so hard.
- We would like to run the phase III study in Asia-Pacific countries/regions.

Hematologic diseases with the indication of alloHSCT Organ function tolerable for full conditioning 18-60 years; PS 0 or 1



disease risk, hospital, age, TBI or non-TBI

Arm A: standard glucose control
Glucose 80-180 mg/dL

Arm B: intensive glucose control Glucose 80-110 mg/dL